Therapix Biosciences Ltd.

Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company dedicated to advancing healthcare through innovative cannabinoid pharmaceuticals. Led by a team of experienced executives and scientists, Therapix Biosciences Ltd. is committed to developing and enhancing a robust portfolio of technologies and assets. The company’s primary address is located at 4 Ariel Sharon St., 16th Floor, Givatayim, 5320047, IL.

Therapix Biosciences Ltd. is focused on several key drug development programs, including THX-110 for the treatment of Tourette syndrome (TS), Obstructive Sleep Apnea (OSA), and Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Therapix Biosciences Ltd. is dedicated to improving patient outcomes through its innovative pharmaceutical solutions.

Therapix Biosciences Ltd. continues to drive advancements in the pharmaceutical industry, ensuring high standards of quality and efficacy. We invite the management team of Therapix Biosciences Ltd. to create a customized and exclusive company showcase and product listing on our platform to further enhance your market presence.